AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20018300
Drug: Thiopental (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental (1 mg/kg)
Trial: 17963857
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive with 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate
Trial: 17963857
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive with 30 mcg ethinyl estradiol and 3 mg drospirenone
Trial: 12407615
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine and nimesulide combination
Trial: 12407615
Drug: Epidural bupivacaine/fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine/fentanyl combination
Trial: 10517037
Drug: Controlled-release (CR)
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled-release (CR) morphine tablets (every 12 h)
Trial: 10517037
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) morphine tablets (every 6 h)
Trial: 8540930
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rHuEPO) 150 U/kg administered intravenously twice a week for 4 weeks in group A (26 infants)
Trial: 8540930
Drug: Erythrocyte transfusion
RxNorm normalized name: erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythrocyte transfusion when hemoglobin levels were less than 10 g/dL with symptoms or less than 8 g/dL in group B (25 infants)
Trial: 2084936
Drug: Fixed minidose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed minidose warfarin (1 mg daily)
Trial: 2084936
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (warfarin and placebo)
Trial: 19797501
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg ACTH (1‐24) administered in the morning
Trial: 19797501
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg ACTH (1‐24) administered in the afternoon
Trial: 15924803
Drug: Xuezhikang (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (0.6 g Bid)
Trial: 11978847
Drug: [11C]NNC 112
FDA approved: no
EMA approved: no
PMDA approved: no
Description: [11C]NNC 112 (D1 receptor antagonist)
Trial: 7649665
Drug: Terminalia Arjuna
RxNorm normalized name: terminalia arjuna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terminalia Arjuna (500 mg 8-hourly)
Trial: 362141
Drug: RA27/3 rubella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RA27/3 rubella vaccine (Almevax)
Trial: 362141
Drug: Cendehill vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cendehill vaccine (Cedevax)
Trial: 29029224
Drug: HZ/su vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZ/su vaccine coadministered with IIV4
Trial: 22013790
Drug: Dengzhan Xixin
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dengzhan Xixin Injection + Chinese decoction + Dengzhan Shengmai Capsule + acupuncture + massage + external washing with Chinese medicine
Trial: 22013790
Drug: Kudiezi Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kudiezi Injection + Chinese decoction + Naoshuantong Capsule + acupuncture + massage + external washing with Chinese medicine
Trial: 22013790
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine control (rehabilitation training and electronic stimulus)
Trial: 18203894
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g UHV-HPMC
Trial: 18203894
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g HV-HPMC
Trial: 18203894
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g HV-HPMC
Trial: 18203894
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g MC
Trial: 18203894
Drug: Control (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2 g cellulose)
Trial: 10521098
Drug: Single IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IUI 34 hours after hCG administration (Group A)
Trial: 10521098
Drug: Double IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double IUI 12 hours and 34 hours after hCG administration (Group B)
Trial: 10521098
Drug: Double IUI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double IUI 34 hours and 60 hours after hCG administration (Group C)
Trial: 8622099
Drug: Isepamicin once
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isepamicin once daily plus ceftriaxone
Trial: 8622099
Drug: Amikacin twice
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin twice daily plus ceftriaxone
Trial: 1828561
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (3 mg daily for 16 weeks)
Trial: 1828561
Drug: Lactose (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (placebo, 3 mg daily for 16 weeks)
Trial: 29306619
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of glucose 10% (50 g glucose)
Trial: 29306619
Drug: 100 mL
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mL of 2% lipid emulsion (soybean 30%, medium chain triglycerides (TG) 30%, olive oil 25%, fish oil 15%, and 20 mg vitamin E)
Trial: 23937849
Drug: Indapamide sustained
RxNorm normalized name: Indapamide
DrugBank: Indapamide (DB00808)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indapamide sustained release tablets and Perindopril
Trial: 11104589
Drug: Alanyl-glutamine supplementation
RxNorm normalized name: Alanyl glutamine
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alanyl-glutamine supplementation (0.5 g/kg BW/day)
Trial: 9046717
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg intramuscularly
Trial: 9046717
Drug: Paracetamol 500
RxNorm normalized name: Paracetamol 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg intramuscularly
Trial: 8314685
Drug: Pravastatin 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20-40 mg/day given at bedtime
Trial: 31352467
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (n=25; female/male=24/1)
Trial: 23098346
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Losartan 100 mg/Hydrochlorothiazide 25 mg)
Trial: 20631555
Drug: 10‐mg aripiprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg aripiprazole for 2 weeks
Trial: 18346606
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg and placebo
Trial: 18346606
Drug: Erythromycin 250
RxNorm normalized name: erythromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 250 mg and ranitidine 150 mg
Trial: 18346606
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg and metoclopramide 10 mg
Trial: 15934081
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with NSAIDs
Trial: 15934081
Drug: On-demand treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand treatment with NSAIDs
Trial: 12870201
Drug: Flutrimazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutrimazole 1% powder applied twice daily for 4 weeks
Trial: 12870201
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% powder applied twice daily for 4 weeks
Trial: 10895107
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (two oral supplements each day during hospital stay)
Trial: 1541318
Drug: Pinacidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinacidil (25 to 100 mg daily for 8 weeks)
Trial: 22878539
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection into neck area
Trial: 22878539
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection into thigh muscle
Trial: 11405173
Drug: Combined adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined adjuvant 5‐fluorouracil‐based chemotherapy and radiotherapy
Trial: 9272360
Drug: Acellular vaccines
RxNorm normalized name: PERTUSSIS VACCINE,ACELLULAR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular vaccines (Chiron Biocine three-component and SmithKline Beecham three-component)
Trial: 9272360
Drug: Whole-cell study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell study vaccine (produced by Connaught Laboratories, Inc.)
Trial: 7944455
Drug: Intra-lymph nodal
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-lymph nodal injection of MMC-CH 40
Trial: 3277804
Drug: Nebulized terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized terbutaline (10 mg)
Trial: 3277804
Drug: Intravenous enprofylline
RxNorm normalized name: etofylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enprofylline (2 mg/kg)
Trial: 23117243
Drug: Glucocorticoid (GC)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (GC) bridging therapy response at 2 weeks
Trial: 23117243
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy arms and baseline DAS
Trial: 21402164
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg D-cycloserine (DCS)
Trial: 21402164
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg valproic acid (VPA)
Trial: 21402164
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 100 mg DCS and 400 mg VPA
Trial: 15635596
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with newer agents (e.g., taxanes)
Trial: 10518852
Drug: Herbal Mouth
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Mouth and Gum Therapy
Trial: 8124953
Drug: IL‐1ra 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra 17 mg/hr
Trial: 8124953
Drug: IL‐1ra 67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra 67 mg/hr
Trial: 8124953
Drug: IL‐1ra 133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra 133 mg/hr
Trial: 8124953
Drug: IL‐1ra treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra treatment in septic shock
Trial: 8124953
Drug: IL‐1ra treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra treatment in Gram-negative infection
Trial: 8124953
Drug: IL‐1ra treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra treatment in patients with IL‐6 > 100 pg/mL
Trial: 8124953
Drug: IL‐1ra treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1ra treatment
Trial: 2536789
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of RIT 4237 attenuated rotavirus vaccine
Trial: 2536789
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of RIT 4237 attenuated rotavirus vaccine
Trial: 30180087
Drug: Glutamate injection
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate injection (1 mol/L or 0.25 mol/L)
Trial: 24507766
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with a mean dose to the whole and inferior rectum
Trial: 24507766
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy with a median volume of rectum treated to ≥70 Gy (V70)
Trial: 24507766
Drug: Low (V25-V40),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low (V25-V40), intermediate (V50-V60), and high (V70-V80) doses to the inferior rectum
Trial: 24507766
Drug: Highest dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest dose (V80) to the mid-rectum
Trial: 18759650
Drug: Sertraline (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (n = 13)
Trial: 12968980
Drug: Laxatives
RxNorm normalized name: LAXATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxatives
Trial: 12968980
Drug: Anticholinergic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic and antispasmodic agents
Trial: 10579482
Drug: 0.8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg/kg dextromethorphan
Trial: 10579482
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg dextromethorphan
Trial: 10579482
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg dextromethorphan
Trial: 10579482
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg dextromethorphan
Trial: 10579482
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg dextromethorphan
Trial: 8841152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg dextromethorphan
Trial: 7574017
Drug: Propofol (1.5‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + propofol infusion (75‐160 micrograms.kg‐1.min‐1 IV)
Trial: 7574017
Drug: Propofol (1.5‐2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5‐2.0 mg/kg, intravenously) + nitrous oxide 60% in oxygen + sevoflurane (1%‐2% end‐tidal)
Trial: 1817766
Drug: Class 1C
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class 1C antiarrhythmic drugs
Trial: 1817766
Drug: Non-pharmacological treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological treatments (catheter ablation and surgery)
Trial: 1817766
Drug: Class 1A
RxNorm normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Class 1A antiarrhythmic drugs (disopyramide or quinidine)
Trial: 6271841
Drug: Topical delta
RxNorm normalized name: Delta Tritex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical delta 9-tetrahydrocannabinol (THC) in light mineral oil vehicles (0.05% and 0.1% solutions)
Trial: 31164169
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 2400 mg oral, delivered as a take-home medication for 12 weeks
Trial: 31164169
Drug: Placebo, matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, matched to NAC, delivered as a take-home medication for 12 weeks
Trial: 29801063
Drug: IAI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAI monotherapy
Trial: 25252192
Drug: mpHBV (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mpHBV (1 mL intramuscular dose containing 40 μg HBsAg)
Trial: 25252192
Drug: Licensed hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed hepatitis B vaccine (1 mL intramuscular dose as two injections, each containing 20 μg HBsAg; total 40 μg HBsAg)
Trial: 22762143
Drug: LAM+DNA vaccine
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM+DNA vaccine
Trial: 22762143
Drug: LAM monotherapy
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAM monotherapy
Trial: 20054409
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRHa) treatment with leuprolide acetate (3.75 mg) subcutaneously every 4 weeks during chemotherapy
Trial: 18312044
Drug: Quetiapine (100-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (100-800 mg/day)
Trial: 18312044
Drug: Risperidone (0.5-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5-4 mg/day)
Trial: 12115174
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg infliximab every 8 weeks
Trial: 12115174
Drug: Decreasing dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreasing dosing interval from 8 weeks to 6 weeks
Trial: 9834004
Drug: Generic carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic carbamazepine formulations
Trial: 9834004
Drug: Innovator carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator carbamazepine formulation
Trial: 2557513
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium diethyldithiocarbamate (DTC)
Trial: 8084808
Drug: Acebutolol 400
RxNorm normalized name: acebutolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 400 mg daily
Trial: 336378
Drug: Acebutolol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 600 mg daily
Trial: 336378
Drug: Acebutolol 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol 1200 mg daily
Trial: 31729607
Drug: Buccal mucosal-advancement
RxNorm normalized name: Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal mucosal-advancement flap
Trial: 31060374
Drug: Esmolol (β1‐AR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (β1‐AR blocker)
Trial: 26712287
Drug: Bupivacaine 0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25%, 1 mL/kg for caudal epidural block
Trial: 26712287
Drug: Bupivacaine 0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg
Trial: 26712287
Drug: Bupivacaine 0.25%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25%, 1 mL/kg with IV midazolam 0.1 mg/kg and ketamine 0.3 mg/kg
Trial: 15578395
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment with IFN (10 MU every 2 days) and ribavirin (1-1.2 g/day)
Trial: 11410923
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MUP parameters
Trial: 9400771
Drug: Chemoreduction with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoreduction with vincristine, etoposide, and carboplatin (VEC) for 6 cycles + adjuvant treatment (AT)
Trial: 9400771
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (AT)
Trial: 3472467
Drug: Prostaglandin gel
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin gel cervical ripening followed by aggressive induction of labor and delivery
Trial: 26523442
Drug: 38 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38 Gy RBE in 5 treatments (hypofractionated)
Trial: 26523442
Drug: 79.2 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 79.2 Gy RBE in 44 treatments (standard fractionated)
Trial: 26773800
Drug: Augmentation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation group (AG)
Trial: 23446076
Drug: Alfentanil 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 15 mcg/kg
Trial: 22845044
Drug: BTDS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 10 with ketoconazole 200 mg twice daily
Trial: 18060958
Drug: Telephone-administered Pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered Pelvic Floor Distress Inventory (PFDI)
Trial: 18060958
Drug: Telephone-administered Pelvic
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered Pelvic Floor Impact Questionnaire (PFIQ)
Trial: 12853351
Drug: Amifostine (910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (910 mg/m2) with carboplatin and paclitaxel